PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
 
Infect Immun. 1991 November; 59(11): 3889–3894.
PMCID: PMC258973

Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats.

Abstract

Tumor necrosis factor (TNF), a macrophage product released in response to endotoxin and other stimuli, has been shown to be a central mediator of endotoxin or septic shock. However, its highly conserved and wide-ranging physiological effects suggest that it may also be an essential cytokine in the host defense against acute bacterial infection or sepsis. A single nontoxic dose of human recombinant TNF administered intravenously 24 h prior to a lethal infusion of Escherichia coli lipopolysaccharide (LPS) completely prevented acute LPS-induced hypotension, ameliorated tissue injury in the lungs and liver, and improved survival in male Fisher 344 rats. The protective effects of TNF were dose dependent and required a 24-h pretreatment interval. After the infusion of LPS, animals in both groups (TNF-treated animals and saline-pretreated controls) initially appeared acutely ill and had a similar severe metabolic acidosis, indicating that TNF did not inactivate or prevent the toxic effects of LPS. Twelve hours after the administration of TNF, the gene for manganous superoxide dismutase, a mitochondrial enzyme which scavenges toxic reactive oxygen species and is induced during conditions which generate a free radical stress, was expressed in liver tissue, suggesting that the induction of manganous superoxide dismutase may be an important in vivo protective mechanism against cellular injury during lethal endotoxemia.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alexander HR, Sheppard BC, Jensen JC, Langstein HN, Buresh CM, Venzon D, Walker EC, Fraker DL, Stovroff MC, Norton JA. Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest. 1991 Jul;88(1):34–39. [PMC free article] [PubMed]
  • Asoh K, Watanabe Y, Mizoguchi H, Mawatari M, Ono M, Kohno K, Kuwano M. Induction of manganese superoxide dismutase by tumor necrosis factor in human breast cancer MCF-7 cell line and its TNF-resistant variant. Biochem Biophys Res Commun. 1989 Jul 31;162(2):794–801. [PubMed]
  • Bannister JV, Bannister WH, Rotilio G. Aspects of the structure, function, and applications of superoxide dismutase. CRC Crit Rev Biochem. 1987;22(2):111–180. [PubMed]
  • Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. [PubMed]
  • Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. [PubMed]
  • Fraker DL, Stovroff MC, Merino MJ, Norton JA. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med. 1988 Jul 1;168(1):95–105. [PMC free article] [PubMed]
  • Nishijima H, Weil MH, Shubin H, Cavanilles J. Hemodynamic and metabolic studies on shock associated with gram negative bacteremia. Medicine (Baltimore) 1973 Jul;52(4):287–294. [PubMed]
  • Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med. 1990 Aug 1;172(2):599–607. [PMC free article] [PubMed]
  • Sheppard BC, Fraker DL, Norton JA. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery. 1989 Aug;106(2):156–162. [PubMed]
  • Sheppard BC, Venzon D, Fraker DL, Langstein HN, Jensen JC, Norton JA. Prolonged survival of tumor-bearing rats with repetitive low-dose recombinant tumor necrosis factor. Cancer Res. 1990 Jul 1;50(13):3928–3933. [PubMed]
  • Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, 3rd, Zentella A, Albert JD, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. [PubMed]
  • Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. [PubMed]
  • Tsan MF, White JE, Santana TA, Lee CY. Tracheal insufflation of tumor necrosis factor protects rats against oxygen toxicity. J Appl Physiol (1985) 1990 Mar;68(3):1211–1219. [PubMed]
  • Tsan MF, White JE, Treanor C, Shaffer JB. Molecular basis for tumor necrosis factor-induced increase in pulmonary superoxide dismutase activities. Am J Physiol. 1990 Dec;259(6 Pt 1):L506–L512. [PubMed]
  • Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R, Mark DF. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science. 1985 Apr 12;228(4696):149–154. [PubMed]
  • Wong GH, Elwell JH, Oberley LW, Goeddel DV. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell. 1989 Sep 8;58(5):923–931. [PubMed]
  • Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science. 1988 Nov 11;242(4880):941–944. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)